Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Contributions of Local Farming to Urban Sustainability in the Northeast United States.

Goldstein BP, Hauschild MZ, Fernández JE, Birkved M.

Environ Sci Technol. 2017 Jul 5;51(13):7340-7349. doi: 10.1021/acs.est.7b01011. Epub 2017 Jun 21.

PMID:
28636338
2.

Resistance to rifampicin: a review.

Goldstein BP.

J Antibiot (Tokyo). 2014 Sep;67(9):625-30. doi: 10.1038/ja.2014.107. Epub 2014 Aug 13. Review.

PMID:
25118103
3.

In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T.

J Clin Microbiol. 2010 Jul;48(7):2613-4. doi: 10.1128/JCM.00806-10. Epub 2010 May 26.

4.

Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.

Heine HS, Purcell BK, Bassett J, Miller L, Goldstein BP.

Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. doi: 10.1128/AAC.00820-09. Epub 2010 Jan 4.

5.

Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.

Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B.

J Clin Pharmacol. 2008 Sep;48(9):1063-8. doi: 10.1177/0091270008321273. Epub 2008 Jul 16.

PMID:
18633123
6.

A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.

Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):304-9. doi: 10.1097/QAI.0b013e31817af47a.

PMID:
18545153
7.

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP.

J Clin Microbiol. 2007 Oct;45(10):3151-4. Epub 2007 Aug 1.

8.

Anidulafungin versus fluconazole for invasive candidiasis.

Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ; Anidulafungin Study Group.

N Engl J Med. 2007 Jun 14;356(24):2472-82.

9.

Bactericidal activity and resistance development profiling of dalbavancin.

Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF.

Antimicrob Agents Chemother. 2007 Apr;51(4):1150-4. Epub 2007 Jan 12.

10.
11.

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.

Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ.

Diagn Microbiol Infect Dis. 2006 Feb;54(2):83-7.

PMID:
16458124
13.

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP.

Diagn Microbiol Infect Dis. 2006 Feb;54(2):149-53. Epub 2006 Jan 19.

PMID:
16426793
14.

In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.

Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP.

Int J Antimicrob Agents. 2006 Feb;27(2):174-7. Epub 2006 Jan 18.

PMID:
16414247
15.

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP.

Antimicrob Agents Chemother. 2005 Nov;49(11):4795-7.

16.
17.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii21-4.

PMID:
15750033
18.

Origin, structure, and activity in vitro and in vivo of dalbavancin.

Malabarba A, Goldstein BP.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii15-20. Review.

PMID:
15750032
19.

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T.

Clin Infect Dis. 2004 Sep 15;39(6):770-5. Epub 2004 Aug 27.

PMID:
15472806
20.

In-vitro activity of nisin against clinical isolates of Clostridium difficile.

Bartoloni A, Mantella A, Goldstein BP, Dei R, Benedetti M, Sbaragli S, Paradisi F.

J Chemother. 2004 Apr;16(2):119-21.

PMID:
15216943
21.

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.

Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T; Anidulafungin Invasive Candidiasis Study Group.

Antimicrob Agents Chemother. 2004 Jun;48(6):2021-4.

22.

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group.

Clin Infect Dis. 2003 Nov 15;37(10):1298-303. Epub 2003 Oct 17.

PMID:
14583862
23.

Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafungin.

Odabasi Z, Paetznick V, Goldstein BP, Rex JH, Ostrosky-Zeichner L.

Antimicrob Agents Chemother. 2003 Sep;47(9):3018-20.

24.
25.

Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model.

Goldstein BP, Wei J, Greenberg K, Novick R.

J Antimicrob Chemother. 1998 Aug;42(2):277-8. No abstract available.

PMID:
9738856
26.

Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Climo MW, Patron RL, Goldstein BP, Archer GL.

Antimicrob Agents Chemother. 1998 Jun;42(6):1355-60.

27.

Purpuromycin: an antibiotic inhibiting tRNA aminoacylation.

Kirillov S, Vitali LA, Goldstein BP, Monti F, Semenkov Y, Makhno V, Ripa S, Pon CL, Gualerzi CO.

RNA. 1997 Aug;3(8):905-13.

28.

The effect of ramoplanin coating on colonization by Staphylococcus aureus of catheter segments implanted subcutaneously in mice.

Romanò G, Berti M, Goldstein BP, Williams R.

J Antimicrob Chemother. 1997 May;39(5):659-61.

PMID:
9184369
29.

Antimicrobial activities of chemically modified thiazolyl peptide antibiotic MDL 62,879 (GE2270A).

Lociuro S, Tavecchia P, Marzorati E, Landini P, Goldstein BP, Denaro M, Ciabatti R.

J Antibiot (Tokyo). 1997 Apr;50(4):344-9.

30.

Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections.

Trani A, Dallanoce C, Panzone G, Ripamonti F, Goldstein BP, Ciabatti R.

J Med Chem. 1997 Mar 14;40(6):967-71.

PMID:
9083486
31.

Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 and its aglycone.

Hermann R, Ripamonti F, Romanò G, Restelli E, Ferrari P, Goldstein BP, Berti M, Ciabatti R.

J Antibiot (Tokyo). 1996 Dec;49(12):1236-48.

32.

Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121.

Borghi A, Spreafico F, Beretta G, Ferrari P, Goldstein BP, Berti M, Denaro M, Selva E.

J Antibiot (Tokyo). 1996 Jun;49(6):607-9. No abstract available.

33.

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity.

Pavlov AY, Berdnikova TF, Olsufyeva EN, Miroshnikova OV, Filipposyanz ST, Preobrazhenskaya MN, Sottani C, Columbo L, Goldstein BP.

J Antibiot (Tokyo). 1996 Feb;49(2):194-8.

34.

Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization.

Selva E, Gastaldo L, Saddler GS, Toppo G, Ferrari P, Carniti G, Goldstein BP.

J Antibiot (Tokyo). 1996 Feb;49(2):145-9.

35.

In-vitro activity of purpuromycin and MDL 63,604 against microorganisms that cause vaginitis and vaginosis.

Goldstein BP, King A, Ripamonti F, Trani A, Phillips I.

J Antimicrob Chemother. 1995 Dec;36(6):1061-5.

PMID:
8821607
36.

In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.

Bartoloni A, Mantella A, Goldstein BP, Denaro M, Nicoletti P, Paradisi F.

Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1105-8.

PMID:
8681991
37.

Components of the GE2270 complex produced by Planobispora rosea ATCC 53773.

Selva E, Ferrari P, Kurz M, Tavecchia P, Colombo L, Stella S, Restelli E, Goldstein BP, Ripamonti F, Denaro M.

J Antibiot (Tokyo). 1995 Sep;48(9):1039-42. No abstract available.

38.

New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.

Malabarba A, Ciabatti R, Scotti R, Goldstein BP, Ferrari P, Kurz M, Andreini BP, Denaro M.

J Antibiot (Tokyo). 1995 Aug;48(8):869-83.

39.

Antibiotic GE37468 A: a new inhibitor of bacterial protein synthesis. I. Isolation and characterization.

Stella S, Montanini N, Le Monnier F, Ferrari P, Colombo L, Marinelli F, Landini P, Ciciliato I, Goldstein BP, Selva E, et al.

J Antibiot (Tokyo). 1995 Aug;48(8):780-6. Erratum in: J Antibiot (Tokyo) 1995 Dec;48(12):C-3.

40.
41.

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.

Goldstein BP, Candiani G, Arain TM, Romanò G, Ciciliato I, Berti M, Abbondi M, Scotti R, Mainini M, Ripamonti F, et al.

Antimicrob Agents Chemother. 1995 Jul;39(7):1580-8.

42.

Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity.

Malabarba A, Ciabatti R, Kettenring J, Ferrari P, Scotti R, Goldstein BP, Denaro M.

J Antibiot (Tokyo). 1994 Dec;47(12):1493-506.

43.

Differential susceptibilities of enterococcal species to elfamycin antibiotics.

Miele A, Goldstein BP, Bandera M, Jarvis C, Resconi A, Williams RJ.

J Clin Microbiol. 1994 Aug;32(8):2016-8.

44.

Different broth dilution procedures generate different apparent MICs for ramoplanin.

Bartoloni A, Mantella A, Goldstein BP, Denaro M, Paradisi F.

J Antimicrob Chemother. 1994 Jun;33(6):1252-3. No abstract available.

PMID:
7928821
45.

Synergic activity of teicoplanin and ethambutol against Mycobacterium tuberculosis.

Arain TM, Goldstein BP, Scotti R, Resconi A.

J Antimicrob Chemother. 1994 Feb;33(2):359-60. No abstract available.

PMID:
8182025
46.

Effect of protein on ramoplanin broth microdilution minimum inhibitory concentrations.

Scotti R, Dulworth JK, Kenny MT, Goldstein BP.

Diagn Microbiol Infect Dis. 1993 Oct;17(3):209-11.

PMID:
8112029
47.
48.

Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879.

Landini P, Bandera M, Soffientini A, Goldstein BP.

J Gen Microbiol. 1993 Apr;139(4):769-74.

PMID:
8515234
49.

N63-carboxamides of N15-alkyl and N15,N15-dialkyl derivatives of teicoplanin and deglucoteicoplanin.

Malabarba A, Ciabatti R, Kettenring J, Scotti R, Candiani G, Berti M, Pallanza R, Goldstein BP.

J Antibiot (Tokyo). 1993 Apr;46(4):668-75.

50.

Octapeptide derivatives of teicoplanin antibiotics.

Malbarba A, Ciabatti R, Scotti R, Goldstein BP.

J Antibiot (Tokyo). 1993 Apr;46(4):661-7.

Supplemental Content

Loading ...
Support Center